DE60134403D1 - Behandlung des akuten koronaren syndroms mit glp-1 - Google Patents

Behandlung des akuten koronaren syndroms mit glp-1

Info

Publication number
DE60134403D1
DE60134403D1 DE60134403T DE60134403T DE60134403D1 DE 60134403 D1 DE60134403 D1 DE 60134403D1 DE 60134403 T DE60134403 T DE 60134403T DE 60134403 T DE60134403 T DE 60134403T DE 60134403 D1 DE60134403 D1 DE 60134403D1
Authority
DE
Germany
Prior art keywords
glp
acute coronary
coronary syndrome
treatment
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60134403T
Other languages
English (en)
Inventor
Thomas R Coolidge
Mario Ehlers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amylin Pharmaceuticals LLC
Original Assignee
Amylin Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22761398&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60134403(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amylin Pharmaceuticals LLC filed Critical Amylin Pharmaceuticals LLC
Application granted granted Critical
Publication of DE60134403D1 publication Critical patent/DE60134403D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60134403T 2000-05-19 2001-05-18 Behandlung des akuten koronaren syndroms mit glp-1 Expired - Lifetime DE60134403D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20523900P 2000-05-19 2000-05-19
PCT/US2001/015996 WO2001089554A2 (en) 2000-05-19 2001-05-18 Treatment of acute coronary syndrome with glp-1

Publications (1)

Publication Number Publication Date
DE60134403D1 true DE60134403D1 (de) 2008-07-24

Family

ID=22761398

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60134403T Expired - Lifetime DE60134403D1 (de) 2000-05-19 2001-05-18 Behandlung des akuten koronaren syndroms mit glp-1

Country Status (13)

Country Link
US (4) US6706689B2 (de)
EP (1) EP1282436B1 (de)
JP (2) JP4881533B2 (de)
KR (1) KR100518046B1 (de)
CN (2) CN103356996A (de)
AT (1) ATE397938T1 (de)
AU (2) AU2001263230B2 (de)
CA (1) CA2407784C (de)
DE (1) DE60134403D1 (de)
ES (1) ES2307619T3 (de)
HK (1) HK1054681A1 (de)
MX (1) MXPA02011339A (de)
WO (1) WO2001089554A2 (de)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US6670355B2 (en) * 2000-06-16 2003-12-30 Wyeth Method of treating cardiovascular disease
JP4480329B2 (ja) * 2000-10-20 2010-06-16 アミリン・ファーマシューティカルズ，インコーポレイテッド Ｇｌｐ−１ペプチドによる冬眠心筋および糖尿病性心筋症の治療
US7412395B2 (en) * 2000-12-29 2008-08-12 Ge Medical Systems Information Technologies, Inc. Automated scheduling of emergency procedure based on identification of high-risk patient
NZ532427A (en) 2001-09-24 2008-07-31 Imp Innovations Ltd Modification of feeding behavior using PYY (peptide YY) and its agonists such as NPY (neuropeptide Y)
EP1463751B1 (de) 2001-12-21 2013-05-22 Human Genome Sciences, Inc. Albuminfusionsproteine
CA2472882A1 (en) 2002-01-10 2003-07-17 Imperial College Innovations Ltd Use of pyy and glp-1, or an agonist thereof, for the modification of feeding behaviour
US7635463B2 (en) * 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
ATE494010T1 (de) * 2002-02-27 2011-01-15 Pharmain Corp Zusammensetzungen zur abgabe von therapeutika und anderen materialien und verfahren zu ihrer herstellung und verwendung
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
JP2005535569A (ja) * 2002-04-04 2005-11-24 ノボ・ノルデイスク・エー／エス Ｇｌｐ−１アゴニスト及び心臓血管合併症
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
BR0311161A (pt) * 2002-05-21 2005-03-29 Cv Therapeutics Inc Método de tratamento de diabetes
US7192922B2 (en) * 2002-11-19 2007-03-20 Allegheny-Singer Research Institute Method of treating left ventricular dysfunction
US20040209803A1 (en) * 2002-12-19 2004-10-21 Alain Baron Compositions for the treatment and prevention of nephropathy
US7790681B2 (en) * 2002-12-17 2010-09-07 Amylin Pharmaceuticals, Inc. Treatment of cardiac arrhythmias with GLP-1 receptor ligands
JP2006514035A (ja) * 2002-12-17 2006-04-27 アミリン・ファーマシューティカルズ，インコーポレイテッド 心不整脈の予防および治療
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
JP2007514665A (ja) * 2003-12-12 2007-06-07 ミオゲン インコーポレイティッド エノキシモン製剤ならびに心肥大および心不全の治療へのそれらの使用方法
EP1729795B1 (de) 2004-02-09 2016-02-03 Human Genome Sciences, Inc. Albuminfusionsproteine
WO2005092333A1 (en) * 2004-03-22 2005-10-06 Myogen, Inc. (r)-enoximone sulfoxide and its use in the treatment of pde-iii mediated diseases
US20060025463A1 (en) * 2004-03-22 2006-02-02 Michael Bristow Enoximone sulfoxide enantiomers and their use in the treatment of PDE-III mediated diseases
WO2005112977A2 (en) * 2004-04-23 2005-12-01 Pharmain, Ltd. Compositions for treatment with glucagon-like peptide, and methods of making and using the same
DE602005022239D1 (de) * 2004-04-23 2010-08-19 Conjuchem Biotechnologies Inc Festphase zur Verwendung in einem Verfahren zur Reinigung von Albuminkonjugaten
EP1776108A1 (de) * 2004-06-23 2007-04-25 Myogen, Inc. Enoximon-formulierungen und ihre verwendung bei der behandlung von pde-iii-vermittelten erkrankungen
WO2006073890A2 (en) * 2004-12-24 2006-07-13 Amylin Pharmaceuticals, Inc. Use of glp-1 and agonists thereof to prevent cardiac myocyte apoptosis
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
AU2006223161B2 (en) * 2005-03-11 2011-05-12 Endo Pharmaceuticals Solutions Inc. Controlled release formulations of octreotide
US7759312B2 (en) * 2005-03-11 2010-07-20 Endo Pharmaceuticals Solutions Inc. Delivery of dry formulations of octreotide
US8946149B2 (en) 2005-04-11 2015-02-03 Amylin Pharmaceuticals, Llc Use of exendin and analogs thereof to delay or prevent cardiac remodeling
CA2617859A1 (en) 2005-06-30 2007-01-11 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R Glp-1 pharmaceutical compositions
US20090202497A1 (en) * 2005-08-23 2009-08-13 The General Hospital Corporation Use of glp-1, glp-1 derivatives or glp-1 fragments for skin regeneration, stimulation of hair growth, or treatment of diabetes
US8039432B2 (en) * 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect
AU2006330610B2 (en) 2005-12-19 2012-08-16 Pharmain Corporation Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
CA2634495A1 (en) * 2005-12-22 2007-06-28 Conjuchem Biotechnologies Inc. Process for the production of preformed conjugates of albumin and a therapeutic agent
DE602007009377D1 (de) 2006-05-30 2010-11-04 Intarcia Therapeutics Inc Zweiteiliger flussmodulator mit einem internen kanal für ein osmotisches ausgabesystem
US7682356B2 (en) 2006-08-09 2010-03-23 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies for use therein
MX2009001763A (es) * 2006-08-17 2009-02-25 Wellstat Therapeutics Corp Tratamiento combinado para trastornos metabolicos.
TWI343262B (en) * 2006-09-26 2011-06-11 Schering Corp Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
CA2673092A1 (en) * 2006-12-19 2008-06-26 Synergenz Bioscience Limited Methods and compositions for the assessment of cardiovascular function and disorders
ES2463457T3 (es) 2006-12-21 2014-05-28 Paratek Pharmaceuticals, Inc. Derivados de la tetraciclina para el tratamiento de infecciones bacterianas, virales y parasitarias
JP5351884B2 (ja) 2007-04-23 2013-11-27 インターシア セラピューティクス，インコーポレイティド インスリン分泌促進性ペプチドの懸濁製剤及び使用
US7960336B2 (en) 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
US8563527B2 (en) * 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
EP2231191A2 (de) * 2007-12-11 2010-09-29 ConjuChem Biotechnologies Inc. Formulierung von insulinotropen peptid-konjugaten
US20090176892A1 (en) * 2008-01-09 2009-07-09 Pharmain Corporation Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
NZ587179A (en) 2008-01-25 2012-07-27 Theranostics Lab Detection of polymorphisms CYP2C19*17 and CYP2C19*3 in CYP2C19 gene related to antiplatelet drug metabolism (e.g. for clopidogrel metabolism)
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
US8185623B2 (en) 2008-02-29 2012-05-22 Physio-Control, Inc. Selectively routing patient data between field devices and treatment center destinations
US8071537B2 (en) 2008-06-25 2011-12-06 Endo Pharmaceuticals Solutions Inc. Implantable device for the sustained release of a polypeptide
JP5536053B2 (ja) * 2008-06-25 2014-07-02 エンド ファーマスーティカルズ ソリューションズ インコーポレイテッド． 離型剤を有するオクトレオチドインプラント
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
CA2737461A1 (en) 2008-09-19 2010-03-25 Tandem Diabetes Care, Inc. Solute concentration measurement device and related methods
PL2373681T3 (pl) 2008-12-10 2017-07-31 Glaxosmithkline Llc Kompozycje farmaceutyczne albiglutydu
EP2216042A1 (de) 2009-02-09 2010-08-11 Ipsen Pharma S.A.S. GLP1-analoge pharmazeutische Zusammensetzungen
EP2401587A2 (de) 2009-02-27 2012-01-04 Tandem Diabetes Care, Inc. Verfahren und vorrichtungen zur bestimmung des flussreservoirvolumens
US9250106B2 (en) 2009-02-27 2016-02-02 Tandem Diabetes Care, Inc. Methods and devices for determination of flow reservoir volume
EP2429526A1 (de) * 2009-05-14 2012-03-21 Gilead Sciences, Inc. Ranolazin zur behandlung von erkrankungen des zentralnervensystems
US20110152770A1 (en) 2009-07-30 2011-06-23 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
HUE035862T2 (en) 2009-09-28 2018-05-28 Intarcia Therapeutics Inc Rapid development and / or completion of substantially steady-state drug delivery
CA2782056C (en) 2009-11-25 2021-03-09 Arisgen Sa Mucosal delivery of peptides
US20110166888A1 (en) * 2010-01-04 2011-07-07 Physio-Control, Inc. Simplified launching of electronic messages in center for treating patient
EP2555791B1 (de) 2010-04-09 2017-11-01 Sinai Health System Verfahren zur behandlung von erkrankungen des magen-darm-trakts mittels eines glp-1-agonisten
WO2011140176A1 (en) 2010-05-04 2011-11-10 Glaxosmithkline Llc Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection
EP2588490B1 (de) 2010-07-02 2017-02-22 Angiochem Inc. Kurze und d-aminosäure-haltige polypeptide für therapeutische konjugate und ihre verwendungen
ES2610362T3 (es) 2011-01-25 2017-04-27 Viviabiotech, S.L. Derivados de 1,2,4-oxadiazol como fármacos moduladores del receptor para el péptido glp-1
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
US9555186B2 (en) 2012-06-05 2017-01-31 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
BR112015014510A2 (pt) 2012-12-21 2017-11-21 Sanofi Sa agonistas de glp1/gip duais ou de glp1/gip/glucagon trigonais
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
US20160151461A1 (en) * 2013-03-14 2016-06-02 The Trustees Of The University Of Pennsylvania Cardio-Metabolic and Vascular Effects of GLP-1 Metabolites
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
EP3080149A1 (de) 2013-12-13 2016-10-19 Sanofi Duale glp-1-/glucagon-rezeptoragonisten
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
ES2968262T3 (es) 2015-06-03 2024-05-08 I2O Therapeutics Inc Sistemas de colocación de implantes
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
US10492141B2 (en) 2015-11-17 2019-11-26 Tandem Diabetes Care, Inc. Methods for reduction of battery usage in ambulatory infusion pumps
WO2017200943A1 (en) 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
CN110225762A (zh) 2017-01-03 2019-09-10 因塔西亚制药公司 包括glp-1受体激动剂的连续施用和药物的共同施用的方法
CN108939052B (zh) * 2018-09-04 2021-03-16 江苏省中医药研究院 艾塞那肽在制备预防或治疗房颤的药物中的用途
WO2020077129A1 (en) 2018-10-11 2020-04-16 Intarcia Therapeutics, Inc. Human amylin analog polypeptides and methods of use

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4135725C2 (de) * 1991-10-30 1994-05-26 Voith Gmbh J M Innenzahnradpumpe mit zwei Hohlrädern und einem gemeinsamen Ritzel
US5464650A (en) * 1993-04-26 1995-11-07 Medtronic, Inc. Intravascular stent and method
US5424286A (en) * 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5690103A (en) 1996-06-20 1997-11-25 Groth; Torgny Lars Detection/exclusion of acute myocardial infarction using neural network analysis of measurements of biochemical markers
US6277819B1 (en) * 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
EP1566180A3 (de) 1996-08-30 2007-08-08 Eli Lilly & Company Verwendung von GLP-1 oder Analogen zur Behandlung von Myokardinfarkt
WO1998043658A1 (en) * 1997-03-31 1998-10-08 Eli Lilly And Company Glucagon-like peptide-1 analogs
JP2001525371A (ja) * 1997-12-05 2001-12-11 イーライ・リリー・アンド・カンパニー Ｇｌｐ−１製剤
SE9802080D0 (sv) * 1998-06-11 1998-06-11 Hellstroem Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
DE19836617C2 (de) * 1998-08-12 2001-02-08 Ulrich Frei In vitro Verfahren zur Erkennung und Diagnostik akuter koronarer Syndrome
US6376549B1 (en) * 1998-09-17 2002-04-23 Akesis Pharmaceuticals, Inc. Metforimin-containing compositions for the treatment of diabetes
MY155270A (en) 1998-09-24 2015-09-30 Lilly Co Eli Use of glp-1 or analogs in treatment of stroke
US6429197B1 (en) * 1998-10-08 2002-08-06 Bionebraska, Inc. Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain
US6284725B1 (en) * 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
WO2001066135A1 (en) 2000-03-08 2001-09-13 Novo Nordisk A/S Lowering serum lipids
US20030040469A1 (en) * 2000-03-08 2003-02-27 Knudsen Liselotte Bjerre Lowering serum lipids
US6448045B1 (en) * 2000-03-10 2002-09-10 The Regents Of The University Of California Inducing insulin gene expression in pancreas cells expressing recombinant PDX-1
US6471968B1 (en) * 2000-05-12 2002-10-29 Regents Of The University Of Michigan Multifunctional nanodevice platform

Also Published As

Publication number Publication date
EP1282436A2 (de) 2003-02-12
WO2001089554A3 (en) 2002-06-13
CN1462191A (zh) 2003-12-17
CN103356996A (zh) 2013-10-23
ES2307619T3 (es) 2008-12-01
JP2003534289A (ja) 2003-11-18
EP1282436B1 (de) 2008-06-11
JP4881533B2 (ja) 2012-02-22
US7981861B2 (en) 2011-07-19
JP2007145837A (ja) 2007-06-14
HK1054681A1 (en) 2003-12-12
MXPA02011339A (es) 2003-04-25
US20060035836A1 (en) 2006-02-16
KR20030001521A (ko) 2003-01-06
US7056887B2 (en) 2006-06-06
US20020107206A1 (en) 2002-08-08
US6706689B2 (en) 2004-03-16
US20040002454A1 (en) 2004-01-01
CN1462191B (zh) 2013-07-24
AU6323001A (en) 2001-12-03
KR100518046B1 (ko) 2005-10-04
ATE397938T1 (de) 2008-07-15
WO2001089554A2 (en) 2001-11-29
AU2001263230B2 (en) 2005-03-10
CA2407784C (en) 2014-08-26
US20100311662A1 (en) 2010-12-09
CA2407784A1 (en) 2001-11-29

Similar Documents

Publication Publication Date Title
ATE397938T1 (de) Behandlung des akuten koronaren syndroms mit glp- 1
ES2186693T3 (es) Uso combinado del acido hialuronico y de agentes terapeuticos para mejorar el efecto terapeutico.
HK1130422A1 (en) A new use of deferiprone
DK1346041T3 (da) Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom
MXPA02002895A (es) Tratamiento topico de infecciones por estreptococcus.
NO20010844L (no) Regulering av substrataktivitet
SE9702860L (sv) Användning av en stam av Lactobacillus för tillverkning av ett läkemedel för reduktion av fibrinogenhalten i blod
MXPA04000654A (es) Terapia dermica usando derivados de fosfato de agente de transferencia de electrones.
HK1077215A1 (en) A pharmaceutical composition for treatment of acute myocardial infarction
NO20003313D0 (no) Terapeutiske midler
DE60026491D1 (de) Melagatran zur behandlung von entzündungen
DE60116075D1 (de) Behandlung von tumoren mit photodynamischer therapie
SE0004101D0 (sv) New use
ATE293972T1 (de) Behandlung von chronischen schmerzen
AR003979A1 (es) Administracion transdermica de vorozol.
NO20032006D0 (no) Anvendelse av melagatran for fremstilling av et medikament for behandling av ischemiske lidelser
EE200200549A (et) Jagatud doosi teraapia veresooni kahjustava aktiivsusega
AR029160A1 (es) El uso del interferon-alfa pegilado para la preparacion de un medicamento para el tratamiento del carcinoma de celula renal, un kit y el uso del mismo
ATE262362T1 (de) Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung
Molin Discoid lupus erythematosus lesions treated with cryosurgery
NO961180L (no) Transdermal anordning inneholdende (E)-2-(p-fluorfenetyl)-3-fluorallylamin for behandling av Alzheimers sykdom
PT1150680E (pt) Utilizacao de moxonidima para o tratamento apos enfarte cardiaco
RU95108375A (ru) Способ профилактики и лечения коронарогенных повреждений миокарда
RU2002103977A (ru) Способ лечения острого гнойного пиелонефрита
RU2001103672A (ru) Способ лечения больных артериальной гипертензией

Legal Events

Date Code Title Description
8363 Opposition against the patent